Search

There is the notion that dysregulation of executive function (EF), which disrupts behavior and cognitive processes, may explain the emotional impairment which leads to increasing sugar sweetened beverages (SSBs) intake. We aimed to test whether anxiety and depression mediate the association between self-reported problems in EF and sugar sweetened beverage intake in Mexican adults between 18-40 years. An open survey advertised as a 'mental health and sugar sweetened beverages study' was conducted, participants were recruited through Facebook ads. Males and females, between 18-40 years, able to read and write, and currently residing in Mexico were included. We analyzed data using causal mediation analysis with latent variables using a structural equation modelling framework. Significant indirect effects were found for somatic symptoms of depression (ß = 6.601, SE = 2.657, p < .05) and anxiety (ß = .679, SE =.334, p < .05). In depression model no significant direct effects of EF were found in the depression model, however they were found in the anxiety model (ß = 1.335 SE =.566, p < .05). Somatic symptoms of depression were a total mediator, and anxiety a partial mediator. The results suggest that EF increased the probability of emotional symptoms, which led to a higher consumption of SBBs. [ABSTRACT FROM AUTHOR]

People with comorbidities and the male sex are at a higher risk of developing severe COVID-19. In the present study, we aim to investigate the associated factors for infection, severity, and death due to COVID-19 in a population from Nuevo León, México. Epidemiological COVID-19 data were collected from 65 hospitals from December 2020 to May 2022. A total of 75,232 cases were compiled from which 25,722 cases were positive for SARS-CoV-2. Male sex, older age, diabetes, obesity, and hypertension were associated with infection. In addition to the above-mentioned factors, renal disease, cardiovascular disease, and immunosuppression were found to be associated with increased COVID-19 severity. These factors, as well as neurological diseases, are also associated with death due to COVID-19. When comparing the different variants of SARs-CoV-2, the variant B1.1.519 increased the probability of death by 2.23 times compared to the AY.20 variant. Male sex, older age, diabetes, obesity, and hypertension are associated with SARS-CoV-2 infection, severity, and death. Along with the aforementioned comorbidities, renal disease, cardiovascular disease, and immunosuppression are also associated with severity and death. Another factor associated with death is the presence of neurological disease. The SARS-CoV-2 B1.1.519 variant increases the odds of death compared to the SARS-CoV-2 AY.20 variant. [ABSTRACT FROM AUTHOR]

Purpose: This paper is aimed at developing a regression tree model useful to quantify the Money Laundering (ML) risk associated to a customer profile and his contracted products (customer's inherent risk). ML is a risk to which different entities are exposed, but mainly the financial ones because of the nature of their activity, so that they are legally obliged to have an appropriate methodology to analyze and assess such a risk. Design/methodology/approach: This paper uses the technique of regression trees to identify, measure and quantify the ML customer's inherent risk. Findings: After classifying customers as high- or low-risk based on a probability threshold of 0.5, this study finds that customers with 56 months or more of seniority are more risky than those with less seniority; the variables "contracted product" and "customer seniority" are statistically significant; the variables origin, legal entity and economic activity are not statistically significant for classifying customers; institution collection, business products and individual product are the most risky; and the percentage of effectiveness, suggested by the decision tree technique, is around 89.5 per cent. Practical implications: In the daily practice of ML risk management, the two main issues to be considered are: 1) the knowledge of the customer, and 2) the detection of his inherent risk elements. Originality/value: Information from the customer portfolio and his transaction profile is analyzed through BigData and data mining. [ABSTRACT FROM AUTHOR]

Introduction: The end of the coronavirus disease 2019 (COVID-19) pandemic has been declared by the World Health Organization on May 5, 2023. Several vaccines were developed, and new data is being published about their effectiveness. However, the clinical trials for the vaccines were performed before the Omicron variant appeared and there are population groups where vaccine effectiveness still needs to be tested. The overarching goal of the present study was to analyze the effects of COVID-19 vaccination before and after the Omicron variant in patients considering comorbidities in a population from Nuevo Leon, Mexico., Methods: Epidemiological COVID-19 data from the Mexican Social Security Institute were collected from 67 hospitals located in northeastern Mexico, from July 2020 to May 2023, and a total of 669,393 cases were compiled, 255,819 reported a SARS-CoV-2 positive reverse transcription quantitative polymerase chain reaction (RT-qPCR) test or a positive COVID-19 antigen rapid test., Results: Before Omicron (BO, 2020-2021), after 14 days of two doses of COVID-19 vaccine, BNT162b2 and ChAdOx1 vaccines were effective against infection in non-comorbid and all comorbid subgroups, whereas after Omicron (AO, 2022- 2023) there was no significant effectiveness against infection with none of the vaccines. Regarding hospitalization BO, BNT162b2, ChAdOx1, CoronaVac and mRNA-1273 significantly protected non-comorbid patients whereas BNT162b2, ChAdOx1, and mRNA-1273, protected all comorbid subgroups against hospitalization. AO, BNT162b2, ChAdOx1, CoronaVac and mRNA-1273 were effective against hospitalization in non-comorbid patients whereas for most comorbid subgroups BNT162b2, ChAdOx1 and CoronaVac were effective against hospitalization. Non-comorbid patients were protected against death as an outcome of COVID-19 during the BO period with most vaccines whereas a reduction in effectiveness was observed AO with mRNA-1273 vaccines in patients with hypertension, and diabetes mellitus., Discussion: BO, COVID-19 vaccines were effective against infection, hospitalization, and death whereas AO, COVID-19 vaccines failed to protect the population from COVID-19 infection. A varying effectiveness against hospitalization and death is observed AO., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Camacho-Moll, Mata-Tijerina, Gutiérrez-Salazar, Silva-Ramírez, Peñuelas-Urquides, González-Escalante, Escobedo-Guajardo, Cruz-Luna, Corrales-Pérez, Gómez-García and Bermúdez-de León.)

Although primary percutaneous coronary intervention (pPCI) is the treatment of choice in ST-elevation myocardial infarction (STEMI), challenges may arise in accessing this intervention for certain geodemographic groups. Pharmacoinvasive strategy (PIs) has demonstrated comparable outcomes when delays in pPCI are anticipated, but real-world data on long-term outcomes are limited. The aim of the present study was to compare long-term outcomes among real-world patients with STEMI who underwent either PIs or pPCI. This was a prospective registry including patients with STEMI who received reperfusion during the first 12 hours from symptom onset. The primary objective was cardiovascular mortality at 12 months according to the reperfusion strategy (pPCI vs PIs) and major cardiovascular events (cardiogenic shock, recurrent myocardial infarction, and congestive heart failure), and Bleeding Academic Research Consortium type 3 to 5 bleeding events were also evaluated. A total of 799 patients with STEMI were included; 49.1% underwent pPCI and 50.9% received PIs. Patients in the PIs group presented with more heart failure on admission (Killip-Kimbal >I 48.1 vs 39.7, p = 0.02) and had a lower proportion of pre-existing heart failure (0.2% vs 1.8%, p = 0.02) and atrial fibrillation (0.25% vs 1.2%, p = 0.02). No statistically significant difference was observed in cardiovascular mortality at the 12-month follow-up (hazard ratio for PIs 0.74, 95% confidence interval 0.42 to 1.30, log-rank p = 0.30) according to the reperfusion strategy used. The composite of major cardiovascular events (hazard ratio for PIs 0.98, 95% confidence interval 0.75 to 1.29, p = 0.92) and Bleeding Academic Research Consortium type 3 to 5 bleeding rates were also comparable. A low socioeconomic status, Killip-Kimball >2, age >60 years, and admission creatinine >2.0 mg/100 ml were predictors of the composite end point after multivariate analysis. In conclusion, this prospective real-world registry provides additional support that long-term major cardiovascular outcomes and bleeding are not different between patients who underwent PIs versus primary PCI., Competing Interests: Declaration of competing interest Dr. Arias-Mendoza reports a relation with Boehringer Ingelheim, Novartis, Sanofi Aventis, and Novo Nordisk that includes speaking fees. Dr. Gopar-Nieto reports a relation with Novartis that includes speaking fees. Dr. Briseño-De la Cruz reports for a relation with Astra Zeneca, Boehringer Ingelheim, and Boston Scientific that includes speaking fees. Dr. Araiza-Garaygordobil reports a relation with Abbott, Asofarma, Astra Zeneca, Boehringer Ingelheim (Ingelheim, Germany), Eurofarma, Medix, Novartis, Silanes, and Servier that includes speaking fees. He also reports relation with Novartis that includes advisory board activities for Silanes and Servier and Research grants. The remaining authors have no competing interests to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)

Background: Mortality predictive indexes have not been applied to patients in general wards out of the ICU., Methods: Retrolective study aimed to evaluate the value of mortality prediction indexes in a cohort of 944 non-critical patients. Three indexes were evaluated according to their calibration and discriminative power: the Mortality Probability Model II (MPMII), the Simplified Acute Physiology System II (SAPS II) and the Logistic Organ Dysfunction System (LODS). The bivariate calculation of relative risk (RR) to die was performed relative to the group of patients that had an expected probability to die > 10%, calculated by an index. To evaluate the calibration, data were arranged in descending order using the chi2 goodness-of-fit model. To evaluate discrimination power, ROC curves were used., Results: SAPS II, MPM II and LODS predicted significant risks at levels of P < 0.005, (RR = 6.56, 4.03 and 3.44, respectively). Regarding the calibration, the null hypothesis was accepted only by using SAPS II (P = 0.664)., Conclusions: The three evaluated indexes each had a good discriminative capacity to detect non-critical inpatients with high risk to die. SAPS II was the best index to predict mortality, as determined by both the bivariate and the calibration analysis. There is no reason for not using mortality predictive indexes for non-critical inpatients.